NanoSyrinx, a synthetic biology company focused on developing Nanosyringes for targeted intracellular delivery of biologic medicines, has named Thomas J. Farrell as Chief Executive Officer and Director. Farrell succeeds founder Joe Healey, who will continue to support the company in a scientific leadership role. The appointment comes as NanoSyrinx transitions from platform development to building a robust pipeline of first-in-class therapies that leverage its innovative Nanosyringe technology.
Health Technology Insights: The Guthrie Clinic Announces New Chief Digital Officer
Farrell brings more than 25 years of experience in biotherapeutics, leading organizations from early-stage research through pivotal clinical trials. He has founded and served as CEO of two NASDAQ-listed biotechnology companies, raised over $500 million through a combination of private investment, strategic partnerships, and public offerings, and played a central role in advancing next-generation therapies in oncology, immunology, and rare monogenic diseases. Edwin Moses, Chairman of the Board at NanoSyrinx, highlighted Farrell’s expertise as critical for guiding the company from platform innovation to clinical pipeline development, while also expressing gratitude to Healey for his foundational leadership.
Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta
Commenting on his new role, Thomas Farrell said he is excited to help NanoSyrinx bring transformative medicines to patients through precise intracellular delivery. He emphasized that the company’s validated Nanosyringe platform offers a unique opportunity to create new classes of therapies and accelerate clinical development. Farrell previously served as President of Oricell Therapeutics in Shanghai and as founding CEO of Artiva Biotherapeutics and Bellicum Pharmaceuticals, where he led the companies through financing, strategic partnerships, and successful clinical programs. Farrell holds an MBA from Stanford University and a BA in Engineering from the University of Cambridge and will be available at the J.P. Morgan Healthcare Conference in San Francisco to discuss NanoSyrinx’s progress.
Health Technology Insights: Amphista Reveals AMX-883 Preclinical Data for AML Therapy
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
